Full Phase 3 Study Results: Nemolizumab (Nemluvio, Galderma) Improves Core Signs and Symptoms of PN
Patients with prurigo nodularis who were treated with nemolizumab (Nemluvio. Galderma) had significantly higher improvements in itch and skin lesions when compared to those receiving placebo at Week 16, with a rapid and clinically meaningful response on itch and sleep disturbance observed as early as Week 4, according to the Phase 3OLYMPIA 1 trial results. […]